Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| EPRX | PRESS-RELEASE | bullish | 8/10 | Eupraxia Pharmaceuticals released 36-week data from Cohort 9 of its RESOLVE trial, showing robust and sustained symptom | Apr 21, 2026 |
| BNTX | PRESS-RELEASE | neutral | 3/10 | BioNTech announced it will release its first-quarter 2026 financial results on May 5, 2026, followed by a conference cal | Apr 21, 2026 |
| FF | PRESS-RELEASE | neutral | 2/10 | FutureFuel Corp. announced it will release its Q1 2026 financial results after market close on May 11, 2026. The press r | Apr 20, 2026 |
| TRVI | PRESS-RELEASE | neutral | 5/10 | Trevi Therapeutics (TRVI) completed a public offering of 13.34 million shares at $13.00 per share, raising approximately | Apr 20, 2026 |
| BBOT | PRESS-RELEASE | bullish | 7/10 | BBOT announced that the FDA granted Fast Track designation to its pan-KRAS inhibitor BBO-11818 for advanced KRAS-mutant | Apr 20, 2026 |
| CMND | PRESS-RELEASE | neutral | 3/10 | Clearmind Medicine (CMND) issued a press release commending a presidential executive order that prioritizes FDA review o | Apr 20, 2026 |
| HELP | PRESS-RELEASE | neutral | 4/10 | Helus Pharma welcomed a White House Executive Order aimed at accelerating research, regulatory pathways, and patient acc | Apr 20, 2026 |
| CLDI | PRESS-RELEASE | bullish | 7/10 | Calidi Biotherapeutics presented preclinical data at AACR demonstrating its RedTail platform's ability to simultaneously | Apr 20, 2026 |
| KYTX | PRESS-RELEASE | bullish | 8/10 | Kyverna Therapeutics announced positive longer-term follow-up data from the Phase 2 portion of its KYSA-6 trial of miv-c | Apr 20, 2026 |
| BCDA | PRESS-RELEASE | bullish | 8/10 | BioCardia announced a positive outcome from its regulatory consultation with Japan's PMDA, which indicated that existing | Apr 20, 2026 |
| ARTL | PRESS-RELEASE | bullish | 7/10 | Artelo Biosciences announced the publication of a peer-reviewed article supporting FABP5 inhibition as a novel, non-opio | Apr 20, 2026 |
| PBM | PRESS-RELEASE | neutral | 3/10 | Psyence Biomedical Ltd. announced advancements in its vertically integrated ibogaine supply chain through its subsidiary | Apr 20, 2026 |
| NCEL | PRESS-RELEASE | neutral | 5/10 | NewcelX announced an updated corporate presentation highlighting its strategic collaboration with Eledon Pharmaceuticals | Apr 20, 2026 |
| BIIB | PRESS-RELEASE | bullish | 7/10 | Biogen has acquired exclusive rights to felzartamab in the Greater China Region from TJ Biopharma, consolidating full gl | Apr 20, 2026 |
| BCTXL | PRESS-RELEASE | mixed | 6/10 | BriaCell Therapeutics presented three clinical posters at the 2026 AACR Annual Meeting, including Phase 3 data showing p | Apr 20, 2026 |
| CMND | PRESS-RELEASE | bullish | 8/10 | Clearmind Medicine announced that its drug candidate CMND-100 met the primary safety and tolerability endpoint in the Ph | Apr 20, 2026 |
| GLUE | PRESS-RELEASE | bullish | 7/10 | Monte Rosa Therapeutics announced promising preclinical data for its first-in-class CCNE1-directed molecular glue degrad | Apr 20, 2026 |
| PASG | PRESS-RELEASE | mixed | 6/10 | Passage Bio reported updated Phase 1/2 data showing PBFT02 reduced brain atrophy and stabilized plasma NfL in early-stag | Apr 20, 2026 |
| CATX | PRESS-RELEASE | bullish | 7/10 | Perspective Therapeutics announced updated interim results from its Phase 1/2a trial of [212Pb]VMT-α-NET in neuroendocri | Apr 20, 2026 |
| PRLD | PRESS-RELEASE | bullish | 7/10 | Prelude Therapeutics announced positive preclinical data for its lead candidate PRT13722, a first-in-class, selective KA | Apr 20, 2026 |
| OCS | PRESS-RELEASE | mixed | 6/10 | Oculis announced completion of the final patient visit in its Phase 3 DIAMOND program for OCS-01, a topical eye drop tre | Apr 20, 2026 |
| AAPG | PRESS-RELEASE | neutral | 3/10 | Ascentage Pharma announced it will present four preclinical studies at the AACR 2026 Annual Meeting. This is a routine s | Apr 19, 2026 |
| STRO | PRESS-RELEASE | bullish | 7/10 | Sutro Biopharma presented promising preclinical data for its next-generation antibody-drug conjugates (ADCs), including | Apr 19, 2026 |
| MNPR | PRESS-RELEASE | bullish | 8/10 | Monopar Therapeutics announced positive Phase 3 FoCus trial results for ALXN1840 in Wilson disease patients with neurolo | Apr 19, 2026 |
| IMCR | PRESS-RELEASE | bullish | 8/10 | Immunocore announced five-year overall survival data from a Phase 3 trial showing KIMMTRAK doubled survival rates in met | Apr 19, 2026 |
| XENE | PRESS-RELEASE | bullish | 8/10 | Xenon Pharmaceuticals presented positive Phase 3 X-TOLE2 and long-term open-label data for azetukalner in focal onset se | Apr 19, 2026 |
| RVMD | PRESS-RELEASE | bullish | 8/10 | Revolution Medicines announced updated Phase 1 data for zoldonrasib in KRAS G12D non-small cell lung cancer, showing a 5 | Apr 19, 2026 |
| MTEX | PRESS-RELEASE | bearish | 8/10 | Mannatech reported a sharp decline in full-year 2025 financial performance with revenue down 8.3% YoY to $108.0M and a n | Apr 17, 2026 |
| IOVA | PRESS-RELEASE | neutral | 2/10 | Iovance Biotherapeutics granted inducement stock options covering 135,470 shares to twelve new non-executive employees, | Apr 17, 2026 |
| BOLD | PRESS-RELEASE | bullish | 7/10 | Boundless Bio (BOLD) announced preclinical data for its lead candidate BBI-940, a novel oral kinesin degrader targeting | Apr 17, 2026 |